Please select a specialty

Kim A. Papp, MD, PhD, FRCPC

135 Union Street East
Waterloo, Ontario
N2J 1C4

K. Papp Clinical Research 

Specialty: Dermatology

Research Interests: Psoriasis, Psoriatic Arthritis, Eczema, Acne, Onychomycosis, Actinic Keratoses, Seborrheic Dermatitis


Dr. Kim Papp is a Board Certified Dermatologist in Waterloo, Ontario.  He has been conducting clinical trials for the last 19 years.  In the past 10 years, Dr. Papp has conducted over 100 psoriasis studies involving over 2750 psoriasis subjects.  He has been the top enrolling investigator in over 70 international dermatology studies.

Dr. Papp has done Phase I, Phase II and/or Phase III psoriasis studies for the following compounds:

adalimumab (Humira®), AIN457, alefacept, AMG714, AMG827, apremilast (CC-10004), BIRB 796 BS, BIRT 2584XX, BMS-582949, briakinumab (ABT-874), CD 2027, clobex, CP-690,550, CRx-140, cyclosporine, dovobet, dovonex, efalizumab, etanercept, golimumab, ILV094, infliximab, KH 1650, MEDI-507, MEDI-545, methotrexate, onercept, recombinant human interleukin eleven (rhIL-11), roziglitazone maleate, RWJ-445380, tacrolimus, tazorac, ustekinumab (CNTO1275), volclosporine (ISA247)

In addition, Dr. Papp's site has been inspected by the FDA, Health Canada, and the EMEA due to high enrollment in pivotal studies. A Form 483 has not been issued and no significant findings have been noted in any of his inspections. 

Dr. Papp has consulted with or advised over 40 pharmaceutical companies on dermatology compound development and study design. He is an author on over 275 publications and abstracts as a result of his clinical trial work. 


Copyright 2014 Probity Medical Research Inc. All Rights Reserved.